CA
IBRX icon

Clearstead Advisors’s ImmunityBio IBRX Stock Holding History

Clearstead Advisors’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.99M Sell
341,711
-3,989
-1% -$30.2K 0.03% 321
2026
Q1 		$2.65M Buy
345,700
+34,000
+11% +$233K 0.02% 315
2025
Q4 		$617K Buy
311,700
+38,704
+14% +$87.7K 0.01% 596
2025
Q3 		$672K Buy
272,996
+25,501
+10% +$65.7K 0.01% 549
2025
Q2 		$653K Buy
247,495
+11,295
+5% +$30.4K 0.01% 535
2025
Q1 		$711K Buy
236,200
+20,000
+9% +$60.6K 0.01% 489
2024
Q4 		$553K Buy
216,200
+10,200
+5% +$42.5K 0.01% 552
2024
Q3 		$766K Buy
206,000
+17,500
+9% +$81K 0.01% 477
2024
Q2 		$1.19M Buy
+188,500
New +$1.24M 0.02% 354

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Clearstead Advisors's IBRX Position: Q2 2026 in Review

Clearstead Advisors reduced its ImmunityBio (IBRX) stake by 1.2% in Q2 2026, selling an estimated $30.2K and leaving 341,711 shares worth $2.99M. The position accounts for 0.03% of the portfolio, ranked #321.

Clearstead Advisors first reported a position in IBRX in Q2 2024 and has held it in 9 quarters since. 404 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Clearstead Advisors held 341,711 shares of ImmunityBio worth $2.99M as of Q2 2026.
  • Clearstead Advisors sold 3,989 ImmunityBio shares in Q2 2026, an estimated $30.2K.
  • ImmunityBio made up 0.03% of Clearstead Advisors's portfolio in Q2 2026, its #321 holding.
  • Clearstead Advisors first reported a position in ImmunityBio in Q2 2024 and has held it in 9 quarters since.
  • 404 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.